Helix BioPharma Corp. (HBP.TO)
CAD 1.0
(5.26%)
CAD 1.0
(5.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 9.35 Million CAD | 47.91% |
| 2023 | 6.32 Million CAD | 4.74% |
| 2022 | 6.04 Million CAD | -33.85% |
| 2021 | 9.13 Million CAD | 5.98% |
| 2020 | 8.61 Million CAD | 15.0% |
| 2019 | 7.49 Million CAD | -12.33% |
| 2018 | 8.54 Million CAD | -16.72% |
| 2017 | 10.26 Million CAD | 6.26% |
| 2016 | 9.65 Million CAD | 10.03% |
| 2015 | 8.77 Million CAD | 0.48% |
| 2014 | 8.73 Million CAD | 6.16% |
| 2013 | 8.22 Million CAD | -37.28% |
| 2012 | 13.11 Million CAD | -14.64% |
| 2011 | 15.36 Million CAD | -7.83% |
| 2010 | 16.67 Million CAD | 0.35% |
| 2009 | 16.61 Million CAD | 63.94% |
| 2008 | 10.13 Million CAD | -2.16% |
| 2007 | 10.35 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 1.82 Million CAD | 102.45% |
| 2024 Q1 | 1.25 Million CAD | -41.5% |
| 2024 Q4 | 5.28 Million CAD | 190.38% |
| 2024 Q2 | 899 Thousand CAD | -28.19% |
| 2023 Q2 | 1.23 Million CAD | -21.96% |
| 2023 Q1 | 1.58 Million CAD | 42.15% |
| 2023 FY | 6.32 Million CAD | 4.74% |
| 2023 Q4 | 2.14 Million CAD | 57.82% |
| 2023 Q3 | 1.35 Million CAD | 9.62% |
| 2022 Q4 | 1.11 Million CAD | -14.36% |
| 2022 Q3 | 1.3 Million CAD | -32.4% |
| 2022 Q2 | 1.92 Million CAD | 13.56% |
| 2022 Q1 | 1.69 Million CAD | -24.82% |
| 2022 FY | 6.04 Million CAD | -33.85% |
| 2021 Q4 | 2.25 Million CAD | -12.69% |
| 2021 FY | 9.13 Million CAD | 5.98% |
| 2021 Q3 | 2.58 Million CAD | 35.71% |
| 2021 Q2 | 1.9 Million CAD | -20.23% |
| 2021 Q1 | 2.38 Million CAD | 17.64% |
| 2020 Q4 | 2.02 Million CAD | -14.93% |
| 2020 FY | 8.61 Million CAD | 15.0% |
| 2020 Q1 | 2.22 Million CAD | 1.28% |
| 2020 Q2 | 2.24 Million CAD | 0.99% |
| 2020 Q3 | 2.38 Million CAD | 6.38% |
| 2019 Q3 | 2.05 Million CAD | 10.04% |
| 2019 Q2 | 1.86 Million CAD | 34.32% |
| 2019 Q1 | 1.38 Million CAD | -13.04% |
| 2019 FY | 7.49 Million CAD | -12.33% |
| 2019 Q4 | 2.19 Million CAD | 6.93% |
| 2018 Q4 | 1.59 Million CAD | -24.8% |
| 2018 FY | 8.54 Million CAD | -16.72% |
| 2018 Q3 | 2.12 Million CAD | -16.46% |
| 2018 Q2 | 2.53 Million CAD | 10.87% |
| 2018 Q1 | 2.29 Million CAD | 72.83% |
| 2017 Q1 | 3.3 Million CAD | 26.99% |
| 2017 FY | 10.26 Million CAD | 6.26% |
| 2017 Q4 | 1.32 Million CAD | -53.93% |
| 2017 Q3 | 2.87 Million CAD | 3.3% |
| 2017 Q2 | 2.78 Million CAD | -15.71% |
| 2016 Q1 | 2.59 Million CAD | 22.49% |
| 2016 Q2 | 2.2 Million CAD | -15.2% |
| 2016 FY | 9.65 Million CAD | 10.03% |
| 2016 Q4 | 2.6 Million CAD | 15.34% |
| 2016 Q3 | 2.25 Million CAD | 2.36% |
| 2015 FY | 8.77 Million CAD | 0.48% |
| 2015 Q4 | 2.12 Million CAD | 11.46% |
| 2015 Q3 | 1.9 Million CAD | -27.45% |
| 2015 Q2 | 2.62 Million CAD | 23.15% |
| 2015 Q1 | 2.13 Million CAD | 18.14% |
| 2014 Q1 | 2.15 Million CAD | 14.24% |
| 2014 Q3 | 2.11 Million CAD | -20.53% |
| 2014 Q4 | 1.8 Million CAD | -14.71% |
| 2014 Q2 | 2.66 Million CAD | 23.26% |
| 2014 FY | 8.73 Million CAD | 6.16% |
| 2013 Q1 | 2.57 Million CAD | 22.96% |
| 2013 FY | 8.22 Million CAD | -37.28% |
| 2013 Q2 | 1.75 Million CAD | -31.95% |
| 2013 Q4 | 1.88 Million CAD | -14.68% |
| 2013 Q3 | 2.21 Million CAD | 26.3% |
| 2012 Q3 | 3.43 Million CAD | -65.86% |
| 2012 Q4 | 2.09 Million CAD | -39.03% |
| 2012 FY | 13.11 Million CAD | -14.64% |
| 2012 Q2 | 10.06 Million CAD | 156.12% |
| 2012 Q1 | 3.92 Million CAD | 23.01% |
| 2011 Q4 | 3.19 Million CAD | -9.88% |
| 2011 FY | 15.36 Million CAD | -7.83% |
| 2011 Q1 | 4.47 Million CAD | 0.0% |
| 2011 Q2 | 4.46 Million CAD | -0.16% |
| 2011 Q3 | 3.54 Million CAD | -20.66% |
| 2010 FY | 16.67 Million CAD | 0.35% |
| 2009 FY | 16.61 Million CAD | 63.94% |
| 2008 FY | 10.13 Million CAD | -2.16% |
| 2007 FY | 10.35 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.83 Million CAD | -5.885% |
| Eupraxia Pharmaceuticals Inc. | 37.92 Million CAD | 75.327% |
| Microbix Biosystems Inc. | 10.21 Million CAD | 8.424% |
| Medicenna Therapeutics Corp. | 19.66 Million CAD | 52.413% |
| Satellos Bioscience Inc. | 6.64 Million CAD | -40.791% |
| Oncolytics Biotech Inc. | 33.79 Million CAD | 72.309% |
| Sernova Corp. | 41.13 Million CAD | 77.251% |